Alnylam plunges as earnings deliver ‘one-two punch’
Alnylam Pharmaceuticals shares fell nearly 30% after the company lowered 2026 revenue guidance for its transthyretin amyloidosis drugs Amvuttra and Onpattro by $200 million. The estimate was cut to $4.2 billion to $4.5 billion from $4.4 billion to $4.7 billion, citing normalized demand after an early launch spike. Amvuttra quarterly sales were $1.01 billion.
How this was made
The 30-second read
Why it matters
The earnings report includes a surprise franchise guidance reduction and a demand-normalization explanation, which the article frames as a major overhang until late-August trial presentation.
Market read
A surprise guidance cut for the core TTR franchise is the primary catalyst, driving a large market-value drop and extending uncertainty into late-August.
What to watch
The article flags a late-August presentation of a failed eplontersen study; outcomes and interpretation could reframe cross-treatment utility concerns and reduce uncertainty if data are less negative than feared.
Background
Alnylam is competing in the TTR cardiomyopathy market with Amvuttra and Onpattro, amid heightened competition and prior study setbacks affecting perceived utility across patient populations.
Ticker impact
Alnylam cut 2026 guidance for Amvuttra and Onpattro franchise by $200 million, citing normalized demand after an early launch spike.
Bearish bias for the next several sessions, with volatility elevated into the late-August medical meeting.
The article describes a surprise forecast cut tied to franchise revenue, plus ongoing competitive and cross-patient utility concerns that extend the overhang.
Market effects
Raises perceived execution and demand-normalization risk for RNA-focused TTR therapies, potentially pressuring sentiment across competitive amyloidosis names.
Limited direct regional spillover; primarily US biotech sentiment.
Could influence global TTR cardiomyopathy competitive read-through, especially for investors tracking amyloidosis franchise durability.
Counterpoint
The guidance cut may reflect timing and normalization rather than structural loss of demand, and prescription data cited in the article suggests the original range might still be achievable.
Key entities
- drugAmvuttra
Alnylam transthyretin amyloidosis medication; franchise revenue guidance was lowered.
- drugOnpattro
Alnylam transthyretin amyloidosis medication; included in the lowered franchise revenue range.
- drugeplontersen
Bridge/competitor therapy referenced via a July study setback that raised questions about cross-patient utility.
- data providerIqvia
Healthcare data specialist whose prescription tracking is cited as suggesting original predictions could be met.
